Shares of ICON Public Limited (NASDAQ:ICLR – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $279.17.
ICLR has been the topic of a number of recent research reports. Truist Financial lowered their target price on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Robert W. Baird lowered their price objective on ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Leerink Partners reaffirmed an “outperform” rating and set a $255.00 target price (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. William Blair reiterated an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $263.00 price target on shares of ICON Public in a research report on Wednesday, January 15th.
Get Our Latest Stock Analysis on ICLR
Hedge Funds Weigh In On ICON Public
ICON Public Stock Performance
ICLR opened at $185.77 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36. ICON Public has a 12-month low of $174.93 and a 12-month high of $347.72. The firm has a 50 day moving average of $195.57 and a two-hundred day moving average of $229.43. The firm has a market capitalization of $15.00 billion, a PE ratio of 19.49, a P/E/G ratio of 1.86 and a beta of 1.21.
ICON Public (NASDAQ:ICLR – Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. The firm had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. On average, analysts anticipate that ICON Public will post 13.38 EPS for the current year.
About ICON Public
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Read More
- Five stocks we like better than ICON Public
- Industrial Products Stocks Investing
- Can TikTok Stock Picks Really Make You Rich?
- What Are Earnings Reports?
- The “Quality” Rotation: Back to Basics Investing
- Overbought Stocks Explained: Should You Trade Them?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.